Orla CunninghamCSO at UltraHumanSpeaker
Profile
Following a postdoc in cancer cell biology, Orla returned to Ireland to establish Wyeth’s nascent antibody discovery & engineering group which was subsequently acquired by Pfizer. Throughout her career at Pfizer, Orla led multi-disciplinary project teams internally as well as academic collaborations with universities across Ireland & the UK. She has supported pre-clinical programs from conception through development, with a number of these molecules currently progressing through clinical trial.
Before joining Ultrahuman Eight as CSO, Orla was Senior Director of Pfizer’s biotherapeutic discovery & optimization group, sitting on the global leadership team. She has published widely in the field of therapeutic antibody engineering & is co-author of several patents.
Agenda Sessions
Sequential Paratope Refinement Transforms a Polyspecific PD1 Antibody into a Truly Unique Bifunctional PD1/VEGFR2 Antagonist
, 12:00pmView Session